EP4228636A4 - Compositions et procédés pour des médicaments ophtalmiques stables au stockage - Google Patents

Compositions et procédés pour des médicaments ophtalmiques stables au stockage Download PDF

Info

Publication number
EP4228636A4
EP4228636A4 EP21880707.1A EP21880707A EP4228636A4 EP 4228636 A4 EP4228636 A4 EP 4228636A4 EP 21880707 A EP21880707 A EP 21880707A EP 4228636 A4 EP4228636 A4 EP 4228636A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
storage
stable ophthalmic
ophthalmic medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21880707.1A
Other languages
German (de)
English (en)
Other versions
EP4228636A1 (fr
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lenz Therapeutics Operations Inc
Original Assignee
Lenz Therapeutics Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/069,155 external-priority patent/US11273150B2/en
Application filed by Lenz Therapeutics Operations Inc filed Critical Lenz Therapeutics Operations Inc
Publication of EP4228636A1 publication Critical patent/EP4228636A1/fr
Publication of EP4228636A4 publication Critical patent/EP4228636A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
EP21880707.1A 2020-10-13 2021-04-28 Compositions et procédés pour des médicaments ophtalmiques stables au stockage Pending EP4228636A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/069,155 US11273150B2 (en) 2018-10-10 2020-10-13 Compositions and methods for the treatment of presbyopia
PCT/US2021/029536 WO2022081204A1 (fr) 2020-10-13 2021-04-28 Compositions et procédés pour des médicaments ophtalmiques stables au stockage

Publications (2)

Publication Number Publication Date
EP4228636A1 EP4228636A1 (fr) 2023-08-23
EP4228636A4 true EP4228636A4 (fr) 2024-11-27

Family

ID=81209258

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21880707.1A Pending EP4228636A4 (fr) 2020-10-13 2021-04-28 Compositions et procédés pour des médicaments ophtalmiques stables au stockage

Country Status (8)

Country Link
EP (1) EP4228636A4 (fr)
JP (1) JP2023544918A (fr)
KR (1) KR20230131822A (fr)
CN (1) CN116847841A (fr)
AU (1) AU2021361731A1 (fr)
CA (1) CA3195422A1 (fr)
MX (1) MX2023004298A (fr)
WO (1) WO2022081204A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2023091439A1 (fr) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Dérivés d'acéclidine, leurs compositions et leurs procédés d'utilisation
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200115377A1 (en) * 2018-10-10 2020-04-16 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629852B2 (en) * 2007-10-16 2017-04-25 Sun Pharma Advanced Research Company Ltd. Ophthalmic composition comprising a prostaglandin
US20190038609A1 (en) * 2013-08-28 2019-02-07 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
KR20180014825A (ko) * 2015-06-18 2018-02-09 프레스바이오피아 세라피스, 엘엘씨 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200115377A1 (en) * 2018-10-10 2020-04-16 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
MX2023004298A (es) 2023-08-09
WO2022081204A1 (fr) 2022-04-21
CN116847841A (zh) 2023-10-03
JP2023544918A (ja) 2023-10-25
EP4228636A1 (fr) 2023-08-23
AU2021361731A1 (en) 2023-05-25
CA3195422A1 (fr) 2022-04-21
KR20230131822A (ko) 2023-09-14

Similar Documents

Publication Publication Date Title
EP4228636A4 (fr) Compositions et procédés pour des médicaments ophtalmiques stables au stockage
EP3958846C0 (fr) Compositions de médicaments enrobés et leurs procédés de préparation
EP4051241A4 (fr) Compositions pharmaceutiques d'albumine et de rapamycine
EP3716990A4 (fr) Compositions et procédés de traitement de maladies neurologiques
EP4347859A4 (fr) Compositions d'intégrase et procédés
EP3877381A4 (fr) Benzamides de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
EP4399306A4 (fr) Compositions et procédés de modulation de pah
EP4308701A4 (fr) Compositions à base de transposons ltr et procédés
PL4094754T3 (pl) Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom
EP4146151A4 (fr) Compositions de tensioactif furanique et procédés
EP3570670A4 (fr) Compositions et procédés de traitement de maladies et de troubles du stockage lysosomial
EP4021844A4 (fr) Formulation et conditionnement de compositions
EP4228700A4 (fr) Méthodes et compositions pour la dégradation de protéines ciblées
EP4367198A4 (fr) Compositions géopolymères et procédés
EP4463173A4 (fr) Compositions postbiotiques et méthodes
EP3773654C0 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
EP3953347A4 (fr) Benzyléthers et anilines de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
EP4437108A4 (fr) Compositions et méthodes pour le traitement de troubles neurodégénératifs
EP3884034A4 (fr) Procédés et compositions pour produire des cannabinoïdes
EP4084784A4 (fr) Compositions et méthodes
EP3840745A4 (fr) Méthodes et compositions pour medicaments permettant de traiter des maladies ophthalmiques
EP3576799A4 (fr) Compositions ophtalmiques pour usages thérapeutiques et prophylactiques
EP3600324A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP4392037A4 (fr) Compositions thérapeutiques et méthodes associées
EP4504952A4 (fr) Compositions et méthodes pour troubles musculaires

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230510

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LENZ THERAPEUTICS OPERATIONS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20241030

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20241024BHEP

Ipc: A61K 31/4409 20060101ALI20241024BHEP

Ipc: A61K 31/439 20060101AFI20241024BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_4680/2025

Effective date: 20250128

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LENZ THERAPEUTICS OPERATIONS, INC.